Targeting iron levels to kill specific cancer cells
Selective Killing of FH-/- Cancer Cells by Targeting Cellular Iron Homeostasis
This study is looking at a specific type of hereditary cancer that affects the kidneys, and it aims to find a new treatment that can target and kill the cancer cells without harming healthy cells by focusing on how these cancer cells manage iron.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Arizona NIH-funded |
| Lab location | 1 site (Tucson, United States) |
| Project ID | NIH-10521277 on NIH RePORTER |
What this research studies
This research focuses on a hereditary cancer syndrome called hereditary leiomyomatosis and renal cell cancer (HLRCC), which leads to aggressive kidney tumors that are resistant to standard treatments. The study aims to identify specific vulnerabilities in cancer cells that lack the fumarate hydratase (FH) enzyme, particularly how these cells handle iron. By understanding these unique cellular changes, the researchers plan to develop a targeted treatment that induces cell death in FH-/- cancer cells while sparing normal cells. This approach utilizes a mechanism called ferroptosis, which is dependent on iron levels, to selectively kill the cancer cells.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with hereditary leiomyomatosis and renal cell cancer (HLRCC) who have aggressive papillary renal cell carcinoma type 2.
Not a fit: Patients without HLRCC or those with other types of kidney cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a novel treatment option for patients with HLRCC and related aggressive kidney cancers.
How similar studies have performed: While targeting iron homeostasis in cancer treatment is a relatively novel approach, preliminary studies have shown promise in similar contexts, suggesting potential for success.
Where this research is happening
Tucson, United States
- University of Arizona — Tucson, United States (Active)
Researchers
- Principal investigator: Ooi, Aikseng — University of Arizona
- Study coordinator: Ooi, Aikseng
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.